SCHEMBL3056560

SCHEMBL3056560

CC(C)(C)[Si](C)(C)OCCOc1ccccc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP2C9 P11712 1/20 0.53
ALDH1A1 P00352 3/20 0.49
TDP1 Q9NUW8 2/20 0.40
ADRA2B P18089 1/20 0.40
PTGS1 P23219 1/20 0.40
APP P05067 1/20 0.38
LMNA P02545 3/20 0.37
RECQL P46063 1/20 0.37
DUT P33316 2/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
POLB P06746 1/20 0.35
MCHR1 Q99705 1/20 0.35
NCF1 P14598 5/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4894524 0.92 CYP1A2 (0.56) CYP1A2CYP2C19CYP2C9ALDH1A1TDP1
SCHEMBL6017107 0.88 CYP1A2 (0.39) CYP1A2CYP2C19CYP2C9ALDH1A1DUT
SCHEMBL3369737 0.88 CYP1A2 (0.39) CYP1A2CYP2C19CYP2C9ALDH1A1DUT
SCHEMBL20900528 0.82 TDP1 (0.44) CYP2C19ALDH1A1TDP1LMNARECQL
SCHEMBL22655811 0.82 HTR2C (0.35) CYP1A2CYP2C19CYP2C9ALDH1A1DUT
SCHEMBL12634859 0.81 DUT (0.37) CYP1A2CYP2C19ALDH1A1TDP1LMNA
SCHEMBL14804182 0.81 L3MBTL1 (0.51) CYP1A2CYP2C19CYP2C9ALDH1A1TDP1
SCHEMBL30375395 0.81 DUT (0.37) CYP1A2CYP2C19ALDH1A1TDP1LMNA
SCHEMBL1927440 0.81 HTR7 (0.50) CYP1A2CYP2C19CYP2C9ALDH1A1TDP1
SCHEMBL30923921 0.80 CA12 (0.36) CYP1A2CYP2C19CYP2C9ALDH1A1DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use NOVARTIS AG (CH) 2010-10-14 US disclosed
EP-2211862-A2 CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050228-A2 CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES NOVARTIS AG (CH) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use CSF1R, CSF3R, MSR1 CYP1A2 3941/4885CYP2C19 4220/4885CYP2C9 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.